Ovarian cancer
RecruitingA study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy
A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy
- Disease:Ovarian cancer
- Substances:BevacizumabSacituzumab Tirumotecan
Greece- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
- Sponsor:Merck Sharp & Dohme LLC










